Stayble Therapeutics presents interim data from the ongoing phase 2b study
Stayble Therapeutics AB (“Stayble” or “the Company”) is currently conducting a phase 2b study with the drug candidate STA363. The company has analyzed blinded data and the results show continued good safety and tolerability and indicate good opportunities for a conclusive outcome of the study. Patient recruitment is still affected by the Covid-19 pandemic and the strict measures introduced in the study countries, primarily in Russia. The Board assesses that the slower patient recruitment means that study results can be presented in 2023.“We are very satisfied with our positive interim